# The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL

> **NCT00441025** · PHASE2 · TERMINATED · sponsor: **Mahidol University** · enrollment: 4 (actual)

## Conditions studied

- Peripheral T-Cell Lymphoma

## Interventions

- **DRUG:** Alemtuzumab

## Key facts

- **NCT ID:** NCT00441025
- **Lead sponsor:** Mahidol University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-09
- **Primary completion:** —
- **Final completion:** 2009-08
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** a lack of a potential patient.
- **Last updated:** 2009-06-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00441025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00441025, "The Effectiveness of Alemtuzumab Combination With CHOP to Treat Patients Newly Diagnosed With PTCL". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00441025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*